Disruptive Dose Series with Mark Bard

In this DHCG Disruptive Dose, Mark Bard sits down with Anton Yarovoy, a precision oncology marketing leader with a background in scientific research, to explore what it takes to connect patients with the right therapy at the right time.

In this DHCG Disruptive Dose, Mark Bard sits down with Andrew Lucking, General Counsel at PurpleLab, to explore how the role of in-house legal counsel has evolved in the era of state privacy laws, HIPAA, and healthcare ad tech.

In this DHCG Disruptive Dose, Mark Bard sits down with Craig Romanok, Chief Commercial Officer at Digitas Health / Publicis Health, to explore how pharma marketing has evolved over three decades and what stays constant no matter how much the technology changes.

In this DHCG Disruptive Dose, Mark Bard sits down with Dr. Nadia Khatri, owner and principal at Ochre Signal Advisory, to explore why pharma organizations keep getting change management wrong — and what it’s actually costing them.

In this DHCG Disruptive Dose, Mark Bard speaks with Eric McCulley, Head of Portfolio, US Immunology at UCB, about why the most important question in pharma innovation isn’t what technology to adopt — it’s whether that technology is genuinely serving patients and HCPs.

In this DHCG Disruptive Dose, Mark Bard speaks with Jayne Krahn, SVP Product and Research Operations at M3 MI, about new 2026 Consumer Health Study findings.

In this DHCG Disruptive Dose, Mark Bard speaks with Matt Lasmanis, Chief Digital Officer at Jazz Pharmaceuticals, about leading digital transformation within a mid-size specialty pharma organization.

In this DHCG Disruptive Dose, Mark Bard speaks with Ray Rotolo, CEO and Co-Founder of Populus Health Technologies, about transforming point of care engagement through connected health technology.

In this DHCG Disruptive Dose, Mark Bard speaks with Glenniss Richards, Sr. Director of Media at Bayer, about navigating media strategy and innovation within a large pharmaceutical organization.

In this DHCG Disruptive Dose, Mark Bard speaks with Lauren Lawhon, President at Health Union, about the strategic value of community-based marketing in pharmaceutical engagement.

In this DHCG Disruptive Dose, Mark Bard speaks with Matt Holland, Chief Operating Officer at Healio, about AI’s transformation of medical publishing and HCP information consumption.